Efficacy and Safety of Sitafloxacin in the Treatment of Acute Exacerbation of Bronchiectasis in Adults

Efficacy and Safety of Sitafloxacin in the Treatment of Acute Exacerbation of Bronchiectasis in Adults :A Multi-center, Randomized, Evaluator-blinded, Levofloxacin Parallel-controlled Clinical Study

The treatment of acute exacerbation of bronchiectasis requires comprehensive treatment, and antibacterial drug therapy is the key. The study is a multicenter, randomized, evaluator-blinded, levofloxacin parallel-controlled clinical study designed to evaluate the efficacy and safety of sitafloxacin in the treatment of acute exacerbations of bronchiectasis in adults.

Study Overview

• Status: Active, not recruiting
• Conditions: Acute Exacerbation of Bronchiectasis
• Intervention / Treatment: Drug: anti-infective therapy sitafloxacin; Drug: anti-infective therapy levofloxacin

Detailed Description

Acute exacerbation of bronchiectasis refers to changes in three or more ofthe following six symptoms in patients with bronchiectasis, including cough frequency, increased sputum volume or nature change, increased purulent sputum with or without wheezing, dyspnea, hemoptysis, and (or) general malaise, lasting for 48 hours or more, and clinicians consider that it is necessary to change the current therapeutic regimen for the condition. The treatment of acute exacerbation of bronchiectasis requires comprehensive treatment, and antibacterial drug therapy is the key. Sitafloxacin has a broad antibacterial spectrum. It has good in vivo and in vitro activities against gram-positive bacteria, gram-negative bacteria, anaerobic bacteria and atypical pathogens and it has excellent pharmacokinetic properties, rapid oral absorption, strong tissue permeability and no liver retention, and no inhibition to main liver drug enzymes of human and it shows good activity against many fluoroquinolone-resistant bacteria. The study aims to evaluate efficacy and safety of sitafloxacin in the treatment of acute exacerbations of bronchiectasis in adults.

• Study Type: Interventional
• Enrollment (Anticipated): 256
• Phase: Phase 4

Contacts and Locations

Study Locations

• China
  • Shanghai
    • Shanghai, Shanghai, China, 200433
      • Shanghai Pulmonary Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Patients who older than 18 years old and are diagnosed with acute exacerbations of bronchiectasis Acute exacerbation of bronchiectasis refers to changes in three or more ofthe following six symptoms in patients, including cough frequency, increased sputum volume or nature change, increased purulent sputum with or without wheezing, dyspnea, hemoptysis, and (or) general malaise, lasting for 48 hours or more, and clinicians consider that it is necessary to change the current therapeutic regimen for the condition; It should also be noted that left and right cardiac insufficiency, arrhythmia, pleural effusion, pulmonary embolism, pneumothorax and pneumonia should be noted.
2. Patients who have not accepted antibacterial drug therapy within 48 hours before initiation of administration or who have accepted other antibacterial drug therapy within 48 hours before initiation of administration but not more than 24 hours (excluding use of quinolones), and still present with apparent symptoms of infection

Exclusion Criteria:

Patients complying with any of the following exclusion criteria cannot be enrolled into this trail:

1. Bronchiectaticpatientswith previous sputum examinations suggesting the presence of bronchiectasis of pathogenic

   - Page 3 of 5 - microorganisms resistant to quinolone drugscomplicated with chronic respiratory failure

2. Patients with a previous stable phase BSI score greater than 9
3. Inhaled, oral or intravenous quinolone antibiotics have been used within 1 week before enrollment.
4. Patients who have a history of allergy to any quinolone or fluoroquinolone
5. Patients who have a medical history of pathological changes in the muscle tendon caused by quinolones or fluoroquinolones;
6. Complicatingbronchial asthma, allergic bronchopulmonary aspergillosis, or active tuberculosis, or active non-tuberculous mycobacterial infection that requires standardized treatment;
7. A history of complicating serious cardiovascular diseases, hematopoietic system diseases, etc. (such as: congestive heart failure, clinically significant coronary heart disease, stroke, myocardial infarction and/or stroke that occurred within half a year, clinically significant arrhythmia, known aortic aneurysm, poorly controlled hypertension (systolic blood pressure> 160mmHg, or diastolic blood pressure> 100mmHg, etc.in two or more consecutive detections);
8. Moderate hemoptysis (>30ml in 24h);
9. Complicatingserious systemic diseases and mental disorders;
10. Complicatingdiabetic patients with poor control or fasting blood glucose> 10mmol/L;
11. Complicatingmalignant tumor;
12. Complicating myasthenia gravis and Parkinson's disease;
13. Patients with abnormal liver function test, withAST (GOT) and/or ALT (GPT) higher than 3 times the upper limit of normal, and/or total bilirubin higher than twice the upper limit of normal;
14. Patients with moderate or severe renal hypofunction, withendogenous creatinine clearance rate <50 ml/min (if the examination is not performed, the clearance rate may be calculated from the serum creatinine value using a formula)*;

15. *Cockcroft-Gault Formula i. Male:eCcr(ml/min)=[(140 - age)

    ×weight(kg)]/[72 ×serum creatinine(mg/dl)] ii. Female:eCcr(ml/ min)=[(140 - age) ×weight(kg) × 0.85]/[72 ×serum creatinine(mg/ dl)] or, iii. Male: eCcr(ml/min)= [(140 - age)×weight(kg)×1.23]/serum creatinine(µmol/l) iv. Male:eCcr(ml/min)= [(140 - age)×weight× 1.04]/serum creatinine(µmol/l)

16. Patients with a medical history of prolonged QTc interval,or requiring use of drugs to treat prolonged QTc interval (e.g., Class I or III anti-arrhythmic, as detailed in Appendix 1), or suffering serious cardiac insufficiency (NYHA Functional Class ≥ III, as detailed in Appendix 2);
17. Patients with a medical history of epileptic seizures, or mental disease that may influence the compliance withthe protocol, or with suicide risk, or a history of alcohol or illicit drug abuse;
18. Immunocompromised patients usingglucocorticoids (with the total dose equivalent to prednisone daily or acourse of treatment of more than 2 weeks) or immunosuppressants, etc.;
19. Pregnant or lactating women or women of childbearing age who are preparing to conceive;
20. Those who have participatedin other clinical trials within 3 months prior to screening.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: sitafloxacin group; Oral sitafloxacin (0.1g one time daily) for 10 days	Drug: anti-infective therapy sitafloxacin; anti-infective therapy
ACTIVE_COMPARATOR: levofloxacin group; Oral levofloxacin (0.4g one time daily) for 10 days	Drug: anti-infective therapy levofloxacin; anti-infective therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical effectiveness	The clinical effective rate was the percentage of improved cases in the analysis set cases.	24days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
microbiological discontinuation of Administration	The effective rate of microbiology is the percentage of cases of clearance, hypothetical clearance, replacement and reinfection in the number of evaluable cases in the analysis set.	10days

Collaborators and Investigators

• Sponsor: Shanghai Pulmonary Hospital, Shanghai, China

Study record dates

Study Major Dates

• Study Start (ACTUAL): June 30, 2021
• Primary Completion (ANTICIPATED): December 30, 2023
• Study Completion (ANTICIPATED): June 30, 2024

Study Registration Dates

• First Submitted: November 12, 2021
• First Submitted That Met QC Criteria: April 5, 2022
• First Posted (ACTUAL): April 6, 2022

Study Record Updates

• Last Update Posted (ACTUAL): April 6, 2022
• Last Update Submitted That Met QC Criteria: April 5, 2022
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Bronchial Diseases; Bronchiectasis; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Anti-Bacterial Agents; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors; Anti-Infective Agents, Urinary; Renal Agents; Anti-Infective Agents; Levofloxacin; Ofloxacin; Sitafloxacin
• Other Study ID Numbers: 20211112

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No